Table 3 Summary of reports on SGLT2 inhibitor use in diabetic renal transplant patients
Number of cases | Age (years) mean±SD or (range) | Sex male/female | eGFR (ml/min/1.73 m2) Baseline Changes after SGLT2 inhibitor | HbA1c (%) Baseline Changes after SGLT2 inhibitor | Systolic blood pressure (mmHg) Baseline Changes after SGLT2 inhibitor | Diastolic blood pressure (mmHg) Baseline Changes after SGLT2 inhibitor | Body weight (kg) Baseline Changes after SGLT2 inhibitor | References |
|---|---|---|---|---|---|---|---|---|
14 | 56.5±7.9 | 7/7 | 54.0±23.8 53.5±13.3 | 6.7±0.7 7.1±0.8 | 150±26 145±20 | 86±14 76±11 | 83.7±7.6 78.7±7.7 | [19] |
22 | 63 (31-72) | 17/5 | 66(57-68) 59(52-67) | 6.9(6.5-8.2) 6.9(6.4-7.4) | 143(111-176) 140(100-163) | 76(71-82) 80(74-86) | 92.0(81.8-104.5) 85.0(79.5-97.5) | [20] |
4 (SPKTR) | 49.4±8.9 | 2/2 | 60±14 -4.3±12.2a | 7.4±1.1 *-0.84±1.2 | not provided -6.5±10.8a | not provided -4.8±12a | not provided -2.14±2.8a | [21] |
6 (KTR) | 61.±12.6 | 5/1 | 78±18.2 -4.3±12.2a | 8.6±1.4 -0.84a | not provided -6.5±10.8a | not provided -4.8±12a | not provided -2.14±2.8a | |
24 | 53.8±7.1 | 23/1 | Ccr 86±20 83±18 | 8.5±1.5 7.6±1.0 | 142±21 134±17 | 81±9 79±8 | 78.6±12.1 76.2±10.9 | [22] |
8 | 56.8±13.7 | 6/2 | 75.75±13.38 69.88±14.70 | 9.34±1.36 7.41±1.44 | 135±9.59 126.43±11.46 | 80.63±10.13 74.75±7.25 | BMI 32.74±7.2 27.4±4.2 | [23] |